Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
NCT01388647
Terminated
This study will evaluate the safety and efficacy of eribulin in combination with carboplatin and trastuzumab in the neoadjuvant setting in subjects who are human epidermal growth factor receptor (HER)2 positive and are clinically stage IIA to IIIB. The study regimen will be administered every 3 weeks for a total of 6 cycles followed by definitive surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/30/2015
Locations: Holy Cross Hospital, Fort Lauderdale, Florida +3 locations
Conditions: HER-2 Positive Breast Cancer
Register for Updates
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
NCT00421889
Completed
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Gynecologic Oncology Associates, Newport Beach, California +10 locations
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00004092
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of combination chemotherapy and comparing them to see how well they work in treating patients with high-risk primary stage II or stage III breast cancer.
Gender:
ALL
Ages:
60 years and below
Trial Updated:
07/07/2015
Locations: Banner Good Samaritan Medical Center, Phoenix, Arizona +1 locations
Conditions: Breast Cancer
Register for Updates
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
NCT00873119
Completed
The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Florida Cancer Specialists, Fort Myers, Florida +22 locations
Conditions: Carcinoma of Unknown Primary
Register for Updates
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00634244
Completed
This randomized phase II trial is comparing three different combination chemotherapy regimens to see how well they work in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/02/2015
Locations: University of Alabama at Birmingham, Birmingham, Alabama +19 locations
Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Register for Updates
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
NCT01542047
Terminated
This study is designed to investigate the possibility that use of two similar but distinct drugs used together in treatment of advanced cancer might prove less toxic than either agent used alone, because dosages can be reduced for each agent. This is a phase I study that is designed to measure the frequency and levels of specific side effects when Carboplatin and Pazopanib are used in combination in advanced cancer patients. The possibility that anti-tumor activity will occur is also going to be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2015
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Cancer, Metastatic
Register for Updates
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
NCT00005078
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining tirapazamine, carboplatin, and paclitaxel in treating patients who have advanced malignant solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2015
Locations: City of Hope Medical Center, Duarte, California +3 locations
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT01281150
Completed
This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by blocking them from dividing. Giving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2015
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania +2 locations
Conditions: Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
NCT00535119
Completed
This phase I trial is studying the side effects and best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with advanced solid cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with carbopl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2015
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +6 locations
Conditions: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Register for Updates
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00621049
Completed
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2015
Locations: Northeast Alabama Medical Center, Anniston, Alabama +25 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Trial of Poor Performance Status Patients (ToPPS)
NCT00892710
Completed
The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2015
Locations: Mayo Clinic - AZ, Scottsdale, Arizona +26 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
NCT00060359
Completed
This phase I trial is studying the side effects and best dose of polyglutamate paclitaxel when given together with carboplatin in treating patients with ovarian epithelial, peritoneal, or fallopian tube cancer. Drugs used in chemotherapy such as polyglutamate paclitaxel and carboplatin use different ways to stop tumor cells from dividing so they stop growing or die. Polyglutamate paclitaxel may be able to deliver the drug directly to tumor cells while leaving normal cells undamaged. Combining po... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/07/2015
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Undifferentiated Ovarian Carcinoma
Register for Updates